检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:罗智英[1]
出 处:《井冈山大学学报(自然科学版)》2013年第2期86-88,共3页Journal of Jinggangshan University (Natural Science)
摘 要:目的探讨一种有效、安全、简便的治疗新生儿高胆红素血症的方法。方法将120例患儿随机分成两组,对照组给予蓝光照射等常规治疗,治疗组在常规治疗基础上加用苯巴比妥、双歧杆菌、蒙脱石散三药口服,比较两组治疗有效率、治疗后胆红素水平,以及不良反应的发生率。结果有效率:治疗组为96.7%,对照组为80%,差异有统计学意义,治疗组日均胆红素下降值为(58.91±22.40)μmol/L,对照组为(38.61±21.63)μmol/L,差异有统计学意义,对照组有腹泻、发热、皮疹等较多不良反应,治疗组除个别嗜睡、便秘无明显不良反应。结论苯巴比妥、双歧杆菌四联活菌片、蒙脱石散三药联合应用治疗新生儿高胆红素血症疗效确切,经济方便。Objective: To explore a effective, safe and convenient treatment on neonatal hyperbilirubinemia. Methods: 120 neonates with hyperbilirubinemia were randomly divided into two groups as a control group and a treatment group. Blue light irradiation and other conventional therapy for the control group, an additional treatment of taking phenobarbital, tetralogy of viable bifidobacterium tablets, and montmorillonite powder on the basis of conventional treatment for the treatment group were done. The effective rates, bilirubin levels posttreatment adverse reaction rates between two groups were compared. Results: There was statistically significant difference in effective rates between the two groups, 96.7% for the treatment group and 80% for the control group respectively. The drop-out values of the average daily bilirubin were (58.91 ± 22.40) umol/L for the treatment group and (38.61±21.63) umol/L for the control group respectively, also with statistically significant difference. There were many adverse reactions like diarrhea, fever, tetter etc. in control group, while not obvious adverse reactions except several drowsiness and constipation in treatment group. Conclusion: The combined application of phenobarbital, tetralogy of viable bifidobacterium tablets, and montmorillonite powder could be effective, economical and convenient on neonatal hyperbilirubinemia
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117